Back to top
more

Surmodics (SRDX)

(Real Time Quote from BATS)

$41.78 USD

41.78
54,511

-0.02 (-0.05%)

Updated Jul 24, 2024 11:26 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (103 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Why Is SurModics (SRDX) Down 6.2% Since Last Earnings Report?

SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Shrabana Mukherjee headshot

New Analyst Coverage Puts Spotlight on These 5 Stocks

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

Zacks.com featured highlights include: LexinFintech, Herman Miller, Interactive Brokers, ConnectOne and Surmodics

Zacks.com featured highlights include: LexinFintech, Herman Miller, Interactive Brokers, ConnectOne and Surmodics

Shrabana Mukherjee headshot

5 Stocks to Keep an Eye on as Analysts Initiate Coverage

More analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

Surmodics (SRDX) Q2 Earnings and Revenues Beat Estimates

Surmodics (SRDX) consistently gains traction from its core Medical Devices unit, which witnesses a substantial contribution from the SurVeil pact with Abbott.

Earnings Preview: SurModics (SRDX) Q2 Earnings Expected to Decline

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Invest in Baxter International Now

Baxter (BAX) teams up with bioMerieux to treat acute kidney injury.

Here's Why You Should Buy Masimo (MASI) Stock Right Now

Masimo (MASI) announces CE marking of its Next Generation SedLine brain function monitoring for pediatric patients.

BD's Venovo Gets FDA Nod, Interventional Arm to Get a Boost

Becton, Dickinson (BDX) receives a number of regulatory approvals of late.

Here's Why You Should Invest in Stryker (SYK) Stock Right Now

Stryker (SYK) makes a few lucrative acquisitions in recent times.

Here's Why You Should Hold Becton, Dickinson Stock for Now

Becton, Dickinson's (BDX) MAX enteric viral panel receives FDA clearance.

DENTSPLY's (XRAY) Preliminary Q4 Results Cheer Investors

DENTSPLY (XRAY) expects to see solid performance in Europe and the rest of the world.

Here's Why You Should Buy Varian Medical (VAR) Stock Now

Buoyed by a strong first quarter, Varian Medical (VAR) has kept its fiscal 2019 guidance intact.

Merit Medical (MMSI) Q4 Earnings & Revenues Surpass Estimates

Merit Medical (MMSI) registers solid expansion in adjusted gross margins in fourth-quarter 2018.

Veeva Systems (VEEV) Beats on Q4 Earnings and Revenues

Veeva Systems (VEEV) continues benefiting from its flagship Vault platform in fourth-quarter fiscal 2019.

Wright Medical (WMGI) Q4 Earnings & Revenues Beat Estimates

Wright Medical's (WMGI) top-line growth in fourth-quarter 2018 can be attributed to solid performance by the Upper and the Lower Extremities segments.

Bruker Rides on Robust NANO & CALID Groups, Recent Buyouts

Bruker's (BRKR) CALID and NANO groups hold promise.

Here's Why Investors Should Buy DexCom (DXCM) Stock Now

Solid growth at the Sensor, Transmitter and Receiver segments provide DexCom (DXCM) a competitive edge in the MedTech space.

CVS Health Rides on Aetna Synergy, PBM Selling Season Modest

With regard to its 2019 PBM selling season, CVS Health (CVS) notes that the net benefits from this selling season are expected to be modest on Anthem-related headwinds.

Here's Why Investors Should Hold DaVita (DVA) Stock Now

DaVita (DVA) steadily expands in international markets. Moreover, the company has witnessed Dialysis services in the United States lately.

Medidata's (MDSO) Margins Under Pressure, Competition Rife

Medidata (MDSO) suffers from cutthroat competition in the clinical trial solutions market at the moment.

Will Surmodics Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Surmodics.

Here's Why Investors Should Buy Surmodics (SRDX) Stock Now

Surmodics' (SRDX) solid efforts to improve its research and development stature are likely to prove beneficial in the quarters ahead.

Baxter's Acute Therapies Profile Strong, Competition Rife

Expanding product portfolio and strong presence in the international markets are key positives for Baxter (BAX) at the moment.

Here's Why Investors Should Retain AmerisourceBergen Stock

AmerisourceBergen (ABC) expects to witness solid growth at the Pharmaceutical Distribution segment in the long term.